Delta-like ligand 4 (Dll4) is a Notch ligand that is predominantly expressed in the endothelium. Evidence from xenografts suggests that inhibiting Dll4 may overcome resistance to antivascular endothelial growth factor therapy. The aims of this study were to characterize the expression of Dll4 in breast cancer and assess whether it is associated with inflammatory markers and prognosis. We examined 296 breast adenocarcinomas and 38 ductal carcinoma in situ tissues that were represented in tissue microarrays. Additional whole sections representing 10 breast adenocarcinomas, 10 normal breast tissues, and 16 angiosarcomas were included. Immunohistochemistry was then performed by using validated antibodies against Dll4, CD68, CD14, Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN), CD123, neutrophil elastase, CD31, and carbonic anhydrase 9. Dll4 was selectively expressed by intratumoral endothelial cells in 73% to 100% of breast adenocarcinomas, 18% of in situ ductal carcinomas, and all lactating breast cases, but not normal nonlactating breast. High intensity of endothelial Dll4 expression was a statistically significant adverse prognostic factor in univariate (P ‫؍‬ 0.002 and P ‫؍‬ 0.01) and multivariate analyses (P ‫؍‬ 0.03 and P ‫؍‬ 0.04) of overall survival and relapse-free survival, respectively. Among the inflammatory markers, only CD68 and DC-SIGN were significant prognostic factors in univariate (but not multivariate) analyses of overall survival (P ‫؍‬ 0.01 and 0.002, respectively). In summary, Dll4 was expressed by endothelium associated with breast cancer cells. In these retrospective subset analyses, endothelial Dll4 expression was a statistically significant multivariate prognostic factor. (Am J Pathol
The growth of tumors requires angiogenesis, 1 which is the consequence of increased expression of proangiogenic factors (for example, vascular endothelial growth factor A ͓VEGF͔ 2, 3 ). The expression of VEGF in cancer is controlled by oncogenic signaling, 4 hypoxia, 5 and inflammatory cells. 6 Although there is redundancy among proangiogenic factors in advanced cancer, 7 many in vivo early stage cancer models show VEGF dependence. 8, 9 This observation has been exploited clinically, where the addition of an anti-VEGF antibody (bevacizumab) to first line taxane-based chemotherapy in recurrent/metastatic breast cancer was associated with prolongation of progression free survival (from a median of 5.9 to 11.8 months, P Ͻ 0.001). 10 Nevertheless, there was no statistically significant overall survival benefit, and all patients in this trial eventually progressed after 4 years. 10 Furthermore, a trial evaluating the addition of bevacizumab to capecitabine in previously treated metastatic/advanced breast cancer demonstrated only a 10.7% improvement in response rate and no survival benefit. 11 To date, there are no validated clinical, radiological, or molecular biomarkers that can predict the survival benefit afforded by bevacizumab. [12] [13] [14] [15] Clinical data suggest that antiangiogenic drugs are active in breast cancer, 10, 16 and it may be necessary to identify biomarkers that predict their benefit.
Additional agents that disrupt functional angiogenesis have been developed to target tumors resistant to anti-VEGF therapy. 17, 18 Recent studies have focused on Deltalike ligand 4 (Dll4), a ligand for Notch receptors 1, 3, and 4 [17] [18] [19] that is predominantly expressed by endothelial cells. [17] [18] [19] Transgenic mice in which Dll4 was replaced by a reporter gene showed that Dll4 expression is restricted to large arteries during development. 20, 21 Furthermore, Dll4 heterozygous knockout mice are reported to have defective arterial development 22 and venous malformations. 22 Experimental systems 17, 23, 24 have shown that Dll4-Notch inhibition leads to increased sprouting and branching of vessels in association with gradients of VEGF. Conversely, VEGF blockade causes a reduction in Dll4 expression and vessel sprouting. 17, 18, [23] [24] [25] [26] [27] In addition, endothelial cells transfected with Dll4 down-regulated VEGF receptors KDR and neuropilin1 and showed reduced proliferative and migratory responses to VEGF. 28 The implication of this research is that Dll4-Notch signaling regulates endothelial sprouting and branching to form functional vascular beds, under the control of VEGF and by autoregulation of VEGF signaling. 23 Disruption of Dll4 signaling by overexpression or inhibition of Dll4 may impair angiogenesis, 17, 18 and blockade of Dll4-Notch signaling results in an increased density of nonfunctional vasculature and is associated with a reduction in the growth of human tumor xenografts. 17, 18 Indeed, certain xenografts that are resistant to anti-VEGF therapy are reported to be sensitive to anti-Dll4, 17, 18, 29 and combination treatment with anti-VEGF and anti-Dll4 has additive inhibitory effects on tumor growth. 18 Together these data provide a rationale to target Dll4 in cancer and suggest that Dll4 may have a role in mediating resistance to anti-VEGF therapies.
Besides direct vascular effects, Fung et al 30 showed that Dll4-Notch signaling in macrophages stimulates a proinflammatory response, which may be proangiogenic. 6 Moreover, Shojaei et al 31, 32 have reported that bevacizumab resistance in certain preclinical in vivo cancer models is causally associated with tumor infiltration by myeloid cells.
The characterization of Dll4 protein expression in human cancer is important for the rational design of clinical trials to test the safety and activity of anti-Dll4 therapy. Defining the pattern of Dll4 expression, in association with markers of inflammation, may identify subgroups with distinct clinical behavior and responses to treatment. The aims of this study were to characterize the in situ expression of Dll4 in breast cancer, to assess the association between Dll4 and established markers of inflammation (CD68, CD14, neutrophil elastase, CD123, and Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin [DC-SIGN]) and hypoxia (carbonic anhydrase 9 ͓CA9͔), and to determine the prognostic significance of these markers.
Materials and Methods

Patients and Tissue Samples
Formalin-fixed paraffin-embedded (FFPE) tissues were obtained for 296 sequential patients with breast adeno- Tissue microarrays (TMAs) were assembled as described previously 33 with three replicate cores for each tumor. Tissue from 38 patients with breast ductal carcinoma in situ was also represented in TMAs for analysis. An additional 10 breast adenocarcinomas, five normal breast resections, five normal lactating breast tissues, seven breast angiosarcomas, and nine nonbreast angiosarcomas (five skin, one duodenal, one liver, one pleural, and one vaginal) were also collected (John Radcliffe Hospital) to investigate the expression of Dll4 in whole sections.
Approval was obtained for the use of all human tissue from the local research ethics committee (C02.216). The National Cancer Institute's Reporting Recommendations for Tumor Marker Prognostic Studies criteria were used in the design, analysis, and interpretation of this research. 34 In Situ Hybridization 2) was generated by using T3 RNA polymerase (Promega, Southampton, UK) from a linearized blunt ended vector containing the above insert. Isotopic in situ hybridization, washes, and developing were performed by using previously described methods. 35 In brief, FFPE tissue sections were deparaffinized in xylenes and rehydrated through graded alcohols. Deproteination was performed for 15 minutes at 37°C with 20 g/ml proteinase K (Sigma-Aldrich, Gillingham, UK). Slides were air-dried before hybridization overnight at 55°C. Posthybridization, a series of increasingly stringent washes were performed, and unhybridized probe was digested with 20 mg/ml RNase A (Sigma-Aldrich) for 60 minutes at 37°C. Slides were then dehydrated through a gradient of alcohols, air-dried, and immersed in liquid film emulsion (GE Health care, Chalfont St Giles, UK) for 14 days, before they were developed and counterstained with H&E. In situ hybridization for ␤-actin on a serial section was used as a positive control for mRNA integrity. 42 and Dll4 (clone 242; Regeneron, Tarrytown, NY) 43 was performed either manually or by using a Bond Max immunostaining machine (Leica) as per the manufacturer's instructions with controls for all experiments (tonsil and/or placenta for inflammatory cell markers; renal cell carcinoma for CA9 and CD31; and renal cell carcinoma, normal kidney, FFPE human umbilical vein endothelial cell pellets, and FFPE U87 cell pellets transfected with empty vector or recombinant human Dll4 43 for Dll4). Immunohistochemistry for Dll4 was performed by using an anti-Dll4 monoclonal antibody (the variable regions of this antibody are fully human, and the Fc-domain is mouse; clone 242) that binds to the extracellular domain of human Dll4 (the epitope is in epidermal growth factor-like domains 3 to 5) and generated in VelocImmune mice (Regeneron). In brief, antigen retrieval was performed in target retrieval solution (Dako) by using a Decloaking Chamber (Biocare Medical, Concord, CA). Sections were incubated for 16 hours at 4°C with the primary antibody at 1 g/ml. Bound antibody was labeled with Novolink polymer (Leica), visualized by using 2,3-diaminobenzidine chromogen, and counterstained with hematoxylin.
Immunohistochemistry
Cores were scored as positive for CA9 if membranous/ cytoplasmic expression was observed in Ͼ10% of epithelial cells. Inflammatory markers were scored on a semiquantitative scale, with negative cores scored 0, cores with occasional positive inflammatory cells scored 1, cores with 10 to 30 labeled inflammatory cells scored 2, and cores with Ͼ30 labeled inflammatory cell infiltrate scored 3. CD31 was scored 0 in tumor cores if there were no vessels or Յ10 individual vessel profiles in a core, or scored 1 if there were Ͼ10 profiles. Intensity of Dll4 expression by the endothelium was scored on a semiquantitative scale by two pathologists, with negative cores scored 0, cores with weak expression scored 1, and cores with moderate/strong expression scored 2. The highest intensity score among replicate cores was used as the score for each patient. All assays and analyses were performed blind to the study endpoints.
Statistics
The 2 test was used to evaluate associations between categorical variables. The false discovery rate controlling procedure (threshold, P Ͻ 0.05) was used to eliminate spurious statistical associations as a result of multiple testing. 44 All survival analyses refer to overall survival times, where death from any cause represents an event or relapse-free survival, where first relapse or death from any cause represents an event. The median and mean survival times within each subgroup were estimated from Kaplan-Meier curves. Patients were censored in survival analyses according to the date last seen by a doctor. For univariate and multivariate survival models, Cox regression analysis was used to identify prognostic factors. All statistically significant prognostic factors in univariate analyses were included in the multivariate model. All statistical analyses were performed with SPSS Statistics (version 16.0; SPSS, Chicago, IL). Two-sided P values Ͻ0.05 were considered statistically significant. Cases with missing data were omitted from statistical analyses.
Results
Frequency and Pattern of Expression
Analyses of tumors from the 296 patients yielded informative data on 151 to 252 patients. Results were not available for the remaining cases in certain assays because of exhaustion of TMAs with repeated sectioning and loss of cores. However, all subsets analyzed were representative of the total patient population (Supplemental Table S1 , see http://ajp.amjpathol.org).
The monoclonal antibody (clone 242) that specifically recognizes the extracellular domain of human Dll4 did not stain U87 cells transfected with empty vector, but showed membranous and cytoplasmic staining in U87 cells transfected with recombinant human Dll4 and untransfected human umbilical vein endothelial cells. 43 Normal kidney did not express Dll4, but endothelial cells in renal cell carcinoma showed endothelial expression of Dll4, consistent with previous in situ hybridization results. 43, 45, 46 CA9 and CD31 were expressed in tumor cells adjacent to areas of necrosis and the endothelium of the control renal cell carcinoma tissue, respectively. 47, 48 CD68 and CD14 were expressed predominantly by macrophages present within the germinal centers of control tonsil tissue. 49, 50 Neutrophil elastase was expressed exclusively by neutrophil polymorphs present within control inflamed tonsil tissue. 38 DC-SIGN was expressed specifically by myeloid dendritic cells in control tonsil and Hofbauer cells (specialized placental macrophages) in placental tissue. 37 CD123 was expressed by plasmacytoid dendritic cells in control tonsil tissue. 51 In initial analyses of whole sections, in situ hybridization revealed selective expression of Dll4 by the endothelial component of intra-and peritumoral vessels, irrespective of their size and maturity (Supplemental Figure S1 , see http://ajp.amjpathol.org). By immunohistochemistry, strongly positive cytoplasmic and membranous expression of Dll4 was observed in tumor associated endothelium in 100% (10 of 10) of invasive breast adenocarcinomas (Figure 1, A and B) . No difference was observed in Dll4 expression by endothelium within the tumor compared with endothelium at the invasive edge. In the TMAs, 73% (170 of 232, of which 47 were score 2 and 123 were score 1) of the adenocarcinomas but only 18% (7 of 38, of which six were score 2, and one was score 1) of in situ ductal carcinomas showed endothelial expression of Dll4 (Figure 1, A-G) . Differences between the TMAs and whole sections probably reflect sampling bias, due to core selection. TMAs of breast adenocarcinomas are generally constructed to preferentially represent malignant epithelium (the cell type of interest for most assays) and may, therefore, under represent associated endothelium. Alternatively, the small number of whole sections in this series (n ϭ 10) may be insufficient to estimate accurately the proportion of tumors with endothelial expression of Dll4. Nevertheless, scoring Dll4 in TMA cores is a valid means of assessing microvessel density, equivalent to scoring endothelial staining in three randomly selected high power fields. Staining for CD31 in serial sections revealed that the proportion of endothelium staining for Dll4 varied considerably between tumors, from 0% to 100%. This did not reflect vascular maturity or vessel size.
Nonlactating normal breast tissues (n ϭ 5 breast reduction tissues; Figure 1 , C and D) were negative for Dll4 staining in all cell types. All cases of lactating non-neoplastic breast tissue (n ϭ 5) were positive for Dll4 in all associated endothelium (irrespective of vessel maturity or size), but no other cell types (Supplemental Figure  S2A , see http://ajp.amjpathol.org). Among the seven breast angiosarcomas, three showed strong cytoplasmic and membranous staining for Dll4 in all malignant endothelial cells (Supplemental Figure S2B , see http://ajp. amjpathol.org). One breast angiosarcoma showed Dll4 reactivity on 10% to 20% of malignant endothelial cells and three breast angiosarcomas were negative for Dll4 expression. Of the malignant endothelial cells in the nine nonbreast angiosarcomas, four were negative (one of five skin and one of one vaginal), two were weakly positive (one of one liver and one of five skin), and three were strongly positive (one of one duodenal, one of one pleural, and one of five skin) for Dll4 expression. Macrophages and dendritic cells infiltrating breast adenocarcinomas showed membranous/cytoplasmic immunoreactivity for Dll4 in approximately 10% of tumors (data not shown), consistent with published research. 30 Although not specifically scored, 20% to 60% of tumor cells in approximately 5% of breast adenocarcinomas showed weak cytoplasmic/membranous expression of Dll4 (data not shown), consistent with results in colon cancer. 43, 52 Immunohistochemistry for inflammatory cell markers selectively stained inflammatory cells with appropriate morphology. Cells positive for CD68, a panmyeloid marker, 
org).
All tumor cells adjacent to foci of necrosis were positive for CA9, with a declining gradient of expression seen with increasing distance from the necrotic core. Occasionally CA9 expression was seen in tumor cells without adjacent necrosis. This may reflect transient or early hypoxia that has yet to progress to necrosis.
Associations Between Molecular and Pathological Variables
Dll4 expression was positively associated with CD31 expression, reflecting microvessel density (Supplemental Table S2 , see http://ajp.amjpathol.org). However, the presence of Dll4 positive endothelial cells was not associated with hypoxia, as identified by CA9 expression, in this series of breast adenocarcinomas. Dll4 endothelial expression was associated with the presence of CD68 and CD14 ϩ inflammatory cells, but these associations were not statistically significant after correction for multiple testing. CD31 expression was positively associated with infiltration by CD68, CD14, and neutrophil elastase positive inflammatory cells. Expression of most inflammatory markers was positively associated with each other, suggesting that most inflammatory cell infiltrates contain a mixture of myeloid cells.
Although many correlations were significant, after correction for multiple testing, few associations were observed between molecular markers and clinicopathological data. Lymph node involvement by tumor was significantly associated with both CD68 (P ϭ 0.003) and CD31 (P ϭ 0.01) expression (Table 1) . ER status was negatively associated with Dll4 (P ϭ 0.002), CD14 (P ϭ 0.02), and neutrophil elastase (P ϭ 0.02). The use of chemotherapy was significantly positively associated with CD68 (P ϭ 0.01), neutrophil elastase (P ϭ 0.01), and CA9 (P ϭ 0.001).
Survival
In univariate analyses of overall survival, age Ն50 years, tumor size Ͼ2 cm, lymph node involvement, Dll4 expression (score 2 vs. 0 or score 2 vs. 1), CD68 expression (score 2 vs. 0), DC-SIGN expression (score 1 or 2 vs. 0), and CD31 expression were all adverse prognostic factors ( Table 2 ). In a Cox regression multivariate survival model ( Table 3 ) that included all significant adverse prognostic factors from univariate analyses, only age Ն50 years, lymph node involvement, and Dll4 expression were significantly associated with overall survival (P ϭ 0.004, 0.01, and 0.03, respectively). These variables retain their significance when chemotherapy, radiotherapy, and hormonal therapy are included in the model (P ϭ 0.015, 0.006, and 0.04, respectively).
When Kaplan-Meier curves of overall survival were plotted for patients subgrouped according to Dll4 expression, overlapping curves were seen for patients scoring 0 or 1 (Figure 2A ). However, patients scoring 2 performed significantly worse, with a mean overall survival of 7.4 years (95% confidence interval, 5.7 to 9.0), compared with 11.7 years (95% confidence interval, 10.6 to 12.8) for score 1 and 11.4 years (95% confidence interval, 10.1 to Values presented as 2 (P). *These P values are not significant following correction for multiple testing by the Benjamini and Hochberg false discovery rate controlling procedure with a cut-off ϭ 0.05. All associations are positive unless marked as † negative association. 
Discussion
The addition of an anti-VEGF therapy (bevacizumab) to first-line taxane chemotherapy extends progressionfree survival in breast cancer, yet tumors eventually progress. 10 Moreover, the addition of bevacizumab to chemotherapy has yet to demonstrate a benefit in overall survival in human breast cancer. 10 Biomarkers are currently sought to identify bevacizumab resistance and targets for second-generation antiangiogenic drugs. Dll4 is a Notch ligand that is selectively expressed by endothelium 53 and is regulated by VEGF and hypoxia. 46 Recent data suggest that spatial regulation of Dll4 signaling is involved in forming a functional vascular bed during tumor angiogenesis, 17, 18 and manipulating Dll4-Notch signaling may inhibit tumor growth. 17, 18 Furthermore, there is growing evidence from model systems that Dll4 expression may define a subset of tumors that are resistant to anti-VEGF therapies, 28, 29 and inhibition of Dll4 may overcome bevacizumab resistance. 28, 29 If validated in human cancer patients, these preclinical findings suggest that Dll4 expression may have potential implications for the use of bevacizumab in breast cancer. Indeed characterizing Dll4 expression may better inform appropriate indications for the use of an anti-Dll4 antibody (Regeneron), which has recently entered phase I clinical trials. This is the first study to perform a detailed evaluation of Dll4 expression in breast cancer and to relate Dll4 expression to other known histological and prognostic markers.
Dll4 expression was observed in the cytoplasm and membrane of the endothelium adjacent to invasive breast cancer and the malignant endothelium of angiosarcomas, but not nonlactating normal breast tissue. This is consistent with data from xenografts 17 and in situ hybridization data for Dll4 in bladder cancer 45 and renal cell carcinoma. 46, 53 The lack of expression of Dll4 in the endothelial cells of normal nonlactating breast tissue is in keeping with the lack of VEGF expression and absence of hypoxia in nonlactating breast. 54 Lactating breast showed high levels of Dll4 positive vascular density, comparable with breast cancer, but lower than normal breast lobules. This is suggestive of physiological angiogenesis Vol. 176, No. 4 in lactating breast, driven by VEGF expression in lactating glandular epithelium. 55 These data suggest that strategies targeting Dll4-Notch signaling may selectively affect the endothelium associated with breast cancer and angiosarcomas, but not endothelium associated with normal breast tissue. Although the expression of Dll4 by endothelium within lactating breast tissue may have implications for the use of anti-Dll4 agents in pregnant women, such women are usually excluded from clinical trials. The heterogeneity in expression of Dll4 in angiosarcomas is of interest because this tumor type could be considered for therapies targeting Dll4. However, the numbers of cases in this series are too small to derive firm conclusions. It also demonstrates the need to select patients appropriately if new therapies are being developed.
The pathology studies showed several associations between the pathways. ER status was negatively associated with Dll4, CD14, and neutrophil elastase. This is likely to be due to differing biology of ER ϩ/Ϫ cancers, with a more hypoxic and proinflammatory phenotype in ER Ϫ cancers. The use of chemotherapy was significantly positively associated with CD68, neutrophil elastase, and CA9. This reflects the strategy of treating more aggressive cancers. For example, infiltration by CD68 ϩ myeloid cells was associated with nodal metastasis, adverse pathological stage and, therefore, an increased likelihood of receiving adjuvant chemotherapy. Similarly, CA9 and neutrophil elastase were associated with high-grade ER Ϫ cancers, which are more likely to receive adjuvant chemotherapy. CD31 expression was positively associated with infiltration by CD68, CD14, and neutrophil elastase positive cells. This suggests that inflammatory cells secrete proangiogenic factors and/or that tumors with a high vascular density provide more opportunities for inflammatory cells to infiltrate the stroma.
Dll4 was a statistically significant prognostic factor in multivariate analyses that included established clinicopathological prognostic variables, treatment effects, and a well described panendothelial marker of microvessel density (CD31). One possible explanation for the adverse prognostic effect of Dll4 in breast cancer is that Dll4 expression is mechanistically associated with functional vascular beds, 29 unlike CD31. Therefore, endothelial Dll4 expression may be a closer surrogate marker of functional tumor angiogenesis (providing a medium for progression and metastasis) than microvessel density scores using panendothelial markers. Independent validation of these findings is imperative to confirm both the pattern of Dll4 expression in breast adenocarcinomas and the prognostic significance of endothelial Dll4 expression. This is the first study to provide a comprehensive in situ assessment of inflammatory markers in human breast cancer. The data suggest that macrophages predominate in inflammatory infiltrates, with significant implications for angiogenesis in breast cancer, which has been attributed, in part, to the secretion of proangiogenic factors by macrophages. 56 Consistent with previously published observations, expression of the myeloid cell marker CD68 57 was a weak adverse prognostic factor in univariate analyses of overall survival, but not relapsefree survival. Expression of DC-SIGN, an immature myeloid dendritic cell marker, was also a significant prognostic factor in univariate analyses of overall survival, but not relapse-free survival. However, few tissues expressed DC-SIGN (n ϭ 13), and the statistical significance of these findings was not maintained in multivariate analyses. Studies looking at markers of more mature dendritic cells (CD1a and CD83) 58, 59 suggest that dendritic cell infiltration may be associated with a favorable prognosis, but these markers are likely to detect different dendritic cell subsets from the DC-SIGN positive population. 37 Moreover, the sample size for certain subset analyses is n Ͻ 200 (n ϭ 189 for neutrophil elastase, n ϭ 192 for CD68, and n ϭ 151 for CA9) and analyses may, therefore, be underpowered to detect a statistically significant prognostic impact.
We have previously reported a statistically significant adverse prognostic impact of CA9 in a series of 103 breast cancer whole sections with 6.2-year median follow-up. 60 This study failed to confirm CA9 as a statistically significant prognostic factor in overall survival or relapse free survival in 151 breast cancers represented in TMAs with 10-year median follow-up. The Kaplan-Meier survival curves for CA9 showed it to be a significant adverse prognostic factor in the first 8 years, but, by 16 years' follow-up, this statistical significance was lost (data not shown). Associations between CA9 and negative ER status, and CA9 and high grade morphology were statistically significant in both datasets.
In summary, Dll4 is expressed in cancer associated endothelial cells, but not the endothelium adjacent to nonlactating normal breast epithelium. This study suggests that tumor endothelial expression of Dll4 is a significant prognostic factor in early breast adenocarcinoma. These data may have clinical relevance because preclinical models 28, 29, 61 suggest that assessing which patients express Dll4 in their tumor endothelium may be critical in predicting benefit from anti-VEGF therapies.
